Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The innovation arm of Oxford University gains impact at board level with the addition of the former Minister for Public Health and Innovation and the former Chief Executive of Oxford Instruments.

Nicola Blackwood, the former Minister for Public Health and Innovation and MP for Oxford West and Abingdon, and Jonathan Flint, the former chief executive of the University’s first spinout company Oxford Instruments, have joined Oxford University Innovation’s (OUI) board as non-executive directors.

Nicola Blackwood was Chair of the Science & Technology Select Committee while in Parliament. There, she led inquiries into the science budget, big data, digital skills, space and satellites, and how UK science would be affected by the EU Referendum. As Minister for Public Health and Innovation, she held a portfolio that covered life sciences, mental health, global health security, and public health. Since leaving office, she has taken up a number of board roles, and acts as an advisor to innovation-focused companies.

Jonathan Flint is the President Elect of the Institute of Physics and the former Chief Executive Officer of Oxford Instruments. He has held managing director positions at BAE Systems, Vislink and EADS. At present, Jonathan holds board positions with Stadium plc, the Oxford Trust, and now OUI.

Find out more (Oxford University Innovation website)

Similar stories

Oxford spinout Optellum secures $14m funding to advance pioneering AI-powered lung cancer diagnosis technology

Optellum, a University of Oxford spinout that provides a breakthrough AI platform to diagnose and treat early-stage lung cancer, has raised $14 million in a Series A funding round.

Oxford spinout MiroBio acquired by Gilead Sciences for $405m

The inflammatory diseases company’s rapid ascent and exit underscores the importance of friendships, partnerships and networks in innovation.

Oxford to receive £7 million to turn bright ideas into global opportunities

The University of Oxford has been awarded more than £7 million, the highest amount of funding given to organisations across the UK, in the latest round of UK Research and Innovation’s (UKRI) Impact Acceleration Account (IAA) funding - aimed at fueling the best, brightest and most disruptive ideas from UK research institutions.

Oxford expands the Cartography collaboration with Janssen

The University of Oxford announced today that it has expanded a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by Johnson & Johnson Innovation

Oxford spin-out Optellum attains CE marking for its early lung cancer diagnosis AI technology

The contribution of individual features on clinical imaging scans to the performance of the LCP-CNN cancer risk prediction model developed in Oxford was investigated.

Oxford University retains top spot for spinout generation in the UK

Oxford University has been ranked first in the UK for turning academic research into spinout companies, according to a new report published today by data analyst firm Beauhurst.